We are monitoring the impact of COVID-19 on Biosimulation Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 8463
Share on
Share on

Global Biosimulation Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Product, Application, End-User & Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 8463
Pages: 170

Tags: Tag2, Tag_3

Global Biosimulation Market Size (2021 to 2026):

The global biosimulation market size was valued at USD 1.86 billion in 2021. It is further predicted to grow and worth USD 3.90 billion by 2026, growing at a CAGR of 16% between 2021 to 2026.

A predictive tool is needed to help predict potential drug-increasing biosimulation software adoption by regulatory antibodies production outcomes by simulation of the biological processes involved.


Mounting cases of drug relapse due to acquired drug resistance in diseases such as tuberculosis and other bacterial infections are the biggest driver of the global biosimulation market.

Biosimulation facilitates continued efforts to gain better insights into drug resistance mechanisms and aid the identification of therapies with high potency and lower susceptibility to drug resistance is driving the global biosimulation market. One of the other factors driving the global biosimulation market growth is the rising number of cases of opioid relapse due to acquired drug resistance in diseases such as cancer, tuberculosis, and other bacterial infections. Increased healthcare spending, the advancement of innovative software, and enhanced modeling technology are other factors driving the biosimulation market forward.

An increase in R&D investments in the pharmaceutical and biotechnology industries and Drug research and production costs must be reduced using technologically sophisticated QSP technologies, and biologics are expected to boost the biosimulation market growth. Furthermore, the market's expansion is projected to be fuelled by a strong clinical imperative to develop high-potency, novel medicines. Biosimulation is becoming more popular in the simulation modeling of diabetes mellitus. It is used in conjunction with proteomic and genomic technology to create innovative therapeutic models.

Another trend that has a positive effect on this market is expanding the biosimilars and biologics markets. Also, infrastructure and IT facilities that support research and aid in optimizing existing technologies in the regional markets are expected to propel the market growth. Favorable reimbursement policies in emerging countries stimulate market growth. In addition, increasing investment and funding by the government and private organizations are encouraging market growth. 


The presence of prolonged therapies, such as diabetes, results in poor patient adherence, leading to the formation of drug-resistant bacteria, which ultimately hinders the global biosimulation market.

Prolonged treatments, such as those used to cure diabetes, may lead to impaired patient adherence and the development of drug-resistant bacteria strains, which may obstruct the overall care plan, necessitating biosimulation. Unfavorable regulatory frameworks and reimbursement policies in some regions are expected to restrain the biosimulation market growth. In biosimulation methodology, there is a lack of standardization. In silico or biosimulation technologies in the drug research or manufacturing phase have yet to be standardized by regulatory bodies. One of the growth restraint factors for the market growth is the lack of trained professionals. 

Impact of COVID-19 on the global biosimulation market:

The Emergence of the global pandemic has created a positive impact on the market growth of biosimulation. Healthcare professionals and research institutes are coming forward to provide vaccines for COVID-19. Certara, the world's pioneer in biosimulation, announced the launch of a new biosimulation technology for COVID-19 vaccines, as well as significant improvements to its Immunogenicity and Immuno-oncology QSP systems. Certara has collaborated on these developments with leading multinational pharmaceutical firms to further de-risk and accelerate drug research and growth. Certara's QSP systems hold the potential to strengthen biopharmaceutical research and development and guide decision-making in areas like the formulation of the COVID-19 vaccine. Conventional vaccine development plans can't keep up with determining which vaccines are appropriate for which populations, and there are so many COVID-19 vaccine candidates in the works. Certara is working on a QSP framework for COVID-19 to enable vaccine candidates to be tested across multiple patient populations. This innovative vaccine platform will promote dosing methods for various COVID-19-affected patient cohorts, such as the elderly and infants, by developing interactive patients and virtual trials.




Market Size Available

2021 to 2026

Base Year


Forecast Period

2021 to 2026

Segments Covered

By Type, Application, Product, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Institut Straumann AG (Switzerland), Geistlich (Switzerland), DENTSPLY International (U.S.), Zimmer Biomet (U.S.), Medtronic (Ireland), BioHorizons IPH, Inc. (U.S.), ACE Surgical Supply Company, Inc. (U.S.), RTI Surgical, Inc. (U.S.), LifeNet Health (U.S.), Dentium (Korea)


This research report on the global biosimulation market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2026.

Biosimulation Market - By Product:                

  • Software 
  • Molecular Simulation         
  • In House  
  • Contract Services 

Biosimulation Market - By Application:        

  • Clinical Trials         
  • PKPD        
  • ADME   

Biosimulation Market - By End User:

  • Biotech Research
  • Pharma and Biotech Companies
  • CROs        
  • Regulatory             

Biosimulation Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa


Some of the promising companies operating in the global biosimulation market profiled in the report are Institut Straumann AG (Switzerland), Geistlich (Switzerland), DENTSPLY International (U.S.), Zimmer Biomet (U.S.), Medtronic (Ireland), BioHorizons IPH, Inc. (U.S.), ACE Surgical Supply Company, Inc. (U.S.), RTI Surgical, Inc. (U.S.), LifeNet Health (U.S.) and Dentium (Korea).


  • Certara released an improved version of its Phoenix biosimulation program in June 2020, widely regarded as the industry norm in PK/PD and toxicokinetic modeling and simulation software. The new version has features that improve trial performance, accuracy and save time. This is expected to aid in the growth of the market.
  • Certara announced the launch of a biosimulation tool for COVID-19 vaccines in August 2020. To assess vaccine candidates across different patient groups, the organization has been designing a Quantitative Systems Pharmacology (QSP) framework for COVID-19.
  • To reinforce its partnerships with South Korean companies and universities, Simulations Plus signed a distributor agreement with Quantum Bio Solutions (Q-Bio) in April 2017.

1. Introduction      

               1.1 Market Definition                    

               1.2 Study Deliverables                  

               1.3 Base Currency, Base Year and Forecast Periods

               1.4 General Study Assumptions                 

2. Research Methodology                

               2.1 Introduction   

               2.2 Research Phases                      

    2.2.1 Secondary Research           

    2.2.2 Primary Research 

    2.2.3 Econometric Modelling      

    2.2.4 Expert Validation  

               2.3 Analysis Design                        

               2.4 Study Timeline                         

3. Overview           

               3.1 Executive Summary                

               3.2 Key Inferences                         

               3.3 Epidemology  

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)          

               4.1 Market Drivers                         

               4.2 Market Restraints                   

               4.3 Key Challenges                         

               4.4 Current Opportunities in the Market               

5. Market Segmentation                  

               5.1 Product                       

    5.1.1 Introduction           

    5.1.2 Software  

    5.1.3 Molecular Simulation          

    5.1.4 In House   

    5.1.5 Contract Services  

    5.1.6  Y-o-Y Growth Analysis, By Product

    5.1.7  Market Attractiveness Analysis, By Product             

    5.1.8  Market Share Analysis, By Product              

               5.2 Application                 

    5.2.1 Introduction           

    5.2.2 Clinical Trials          

    5.2.3 PKPD         

    5.2.4 ADME       

    5.3.6 Y-o-Y Growth Analysis, By End-Use Industry              

    5.3.7  Market Attractiveness Analysis, By End-Use Industry          

    5.3.8  Market Share Analysis, By End-Use Industry            

               5.3 End User                     

    5.3.1 Introduction           

    5.3.2 Biotech Research  

    5.3.3 Pharma and Biotech Companies     

    5.3.4 CROs         

    5.3.5 Regulatory              

    5.3.6 Y-o-Y Growth Analysis, By End-Use Industry              

    5.3.7  Market Attractiveness Analysis, By End-Use Industry          

    5.3.8  Market Share Analysis, By End-Use Industry            

6. Geographical Analysis                  

               6.1 Introduction   

    6.1.1 Regional Trends    

    6.1.2 Impact Analysis     

    6.1.3 Y-o-Y Growth Analysis        

          By Geographical Area

          By Product

          By Application

          By End-User

    6.1.4  Market Attractiveness Analysis      

          By Geographical Area

          By Product

          By Application

          By End-User

    6.1.5  Market Share Analysis       

          By Geographical Area

          By Product

          By Application

          By End-User

               6.2 Middle-East    

               6.3 Africa

7. Strategic Analysis            

               7.1 PESTLE analysis                        

    7.1.1 Political    

    7.1.2 Economic 

    7.1.3 Social        

    7.1.4 Technological        

    7.1.5 Legal         

    7.1.6 Environmental       

               7.2 Porter’s Five analysis   

    7.2.1 Bargaining Power of Suppliers         

    7.2.2 Bargaining Power of Consumers     

    7.2.3 Threat of New Entrants      

    7.2.4 Threat of Substitute Products and Services

    7.2.5 Competitive Rivalry within the Industry      

8. Market Leaders' Analysis             

               8.1 Athersys                      

    8.1.1 Overview 

    8.1.2 Product Analysis   

    8.1.3 Financial analysis  

    8.1.4 Recent Developments        

    8.1.5 SWOT analysis       

    8.1.6 Analyst View          

               8.2 Certara (US)               

               8.3 Simulation Plus (US)               

               8.4   Dassault Systèmes (France)               

               8.5 Schrödinger (US)                     

               8.6 ACD/Labs (Canada)                 

               8.7 Chemical Computing Group (Canada)   

               8.8 Physiomics (UK)                       

               8.9 Evidera (US)               

               8.10  In silico biosciences (US)                   

               8.11 INOSIM Software (Germany)  

               8.12 Insilico Biotechnology (Germany)                   

               8.13 LeadInvent Technologies (India)                     

               8.14 Rosa (US)                 

               8.15 Nuventra Pharma (US)                       

               8.16 Genedata (Switzerland)                      

9. Competitive Landscape               

               9.1 Market share analysis 

               9.2 Merger and Acquisition Analysis                       

               9.3 Agreements, collaborations and Joint Ventures

               9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities               


               a) List of Tables                

               b) List of Figures   

  • Global ,Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of market by product ,by application, by end user along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Biosimulation Market By Region, From 2021 to 2026 ( USD Billion )
  2. Global Biosimulation Market By Product, From 2021 to 2026 ( USD Billion )
  3. Global Software  Market By Region, From 2021 to 2026 ( USD Billion )
  4. Global Molecular Simulation Market By Region, From 2021 to 2026 ( USD Billion )
  5. Global In House  Market By Region, From 2021 to 2026 ( USD Billion )
  6. Global Contract Services Market By Region, From 2021 to 2026 ( USD Billion )
  7. Global Biosimulation Market By Application, From 2021 to 2026 ( USD Billion )
  8. Global Clinical Trials Market By Region, From 2021 to 2026 ( USD Billion )
  9. Global PKPD Market By Region, From 2021 to 2026 ( USD Billion )
  10. Global ADME   Market By Region, From 2021 to 2026 ( USD Billion )
  11. Global Biosimulation Market By End User, From 2021 to 2026 ( USD Billion )
  12. Global Biotech Research Market By Region, From 2021 to 2026 ( USD Billion )
  13. Global Pharma and Biotech Companies Market By Region, From 2021 to 2026 ( USD Billion )
  14. Global CROs Market By Region, From 2021 to 2026 ( USD Billion )
  15. Global Regulatory Market By Region, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed


$ 1234 4255

Click for Request Sample